ES2721159T3 - Antígenos asociados a tumor independientes de MHC novedosos - Google Patents

Antígenos asociados a tumor independientes de MHC novedosos Download PDF

Info

Publication number
ES2721159T3
ES2721159T3 ES13818713T ES13818713T ES2721159T3 ES 2721159 T3 ES2721159 T3 ES 2721159T3 ES 13818713 T ES13818713 T ES 13818713T ES 13818713 T ES13818713 T ES 13818713T ES 2721159 T3 ES2721159 T3 ES 2721159T3
Authority
ES
Spain
Prior art keywords
protein
csf2ra
tumor
associated antigens
tumor associated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13818713T
Other languages
English (en)
Inventor
Dirk Schadendorf
Anette Paschen
Silke Lübcke
Martina Fatho
Daniela Eberts
Hakim Echchannaoui
Volker Lennerz
Catherine Wölfel
Thomas Wölfel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biontech RNA Pharmaceuticals GmbH
Original Assignee
Biontech RNA Pharmaceuticals GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biontech RNA Pharmaceuticals GmbH filed Critical Biontech RNA Pharmaceuticals GmbH
Application granted granted Critical
Publication of ES2721159T3 publication Critical patent/ES2721159T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001116—Receptors for cytokines
    • A61K39/001118—Receptors for colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7153—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for colony-stimulating factors [CSF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y503/00—Intramolecular oxidoreductases (5.3)
    • C12Y503/03—Intramolecular oxidoreductases (5.3) transposing C=C bonds (5.3.3)
    • C12Y503/03012—L-Dopachrome isomerase (5.3.3.12)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)

Abstract

Una proteína, fragmento de proteína o polipéptido que comprende al menos 8 aminoácidos contiguos de la secuencia de aminoácidos de la cadena alfa del receptor de GM-CSF (CSF2RA) (SEQ ID NO: 1) para su uso en la prevención o tratamiento de una enfermedad tumoral, en el que el tumor está desprovisto de un complejo de MHC de clase I funcional y muestra escape inmunitario por alteración del complejo de presentación de MHC de clase I, en el que dicha proteína, fragmento de proteína o polipéptido puede inducir una respuesta de linfocitos T y/o unirse a un receptor de linfocitos T equivalente, y en el que el tumor expresa CSF2RA (SEQ ID NO: 1) o una proteína que tiene al menos un 75 % de identidad de secuencia con CSF2RA.
ES13818713T 2012-12-14 2013-12-16 Antígenos asociados a tumor independientes de MHC novedosos Active ES2721159T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12197289 2012-12-14
PCT/EP2013/076760 WO2014091034A1 (en) 2012-12-14 2013-12-16 Novel mhc-independent tumor-associated antigens

Publications (1)

Publication Number Publication Date
ES2721159T3 true ES2721159T3 (es) 2019-07-29

Family

ID=47355928

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13818713T Active ES2721159T3 (es) 2012-12-14 2013-12-16 Antígenos asociados a tumor independientes de MHC novedosos

Country Status (13)

Country Link
US (2) US9861688B2 (es)
EP (1) EP2932264B1 (es)
JP (1) JP6475166B2 (es)
AU (2) AU2013357239B2 (es)
CA (2) CA2894966C (es)
DK (1) DK2932264T3 (es)
ES (1) ES2721159T3 (es)
HU (1) HUE042967T2 (es)
PL (1) PL2932264T3 (es)
PT (1) PT2932264T (es)
SI (1) SI2932264T1 (es)
TR (1) TR201905447T4 (es)
WO (1) WO2014091034A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150130284A (ko) 2013-03-15 2015-11-23 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 암 백신 및 이를 이용한 치료 방법
WO2016133779A1 (en) 2015-02-16 2016-08-25 The Trustees Of The University Of Pennsylvania A fully-human t cell receptor specific for the 369-377 epitope derived from the her2/neu (erbb2) receptor protein
WO2019157454A1 (en) * 2018-02-11 2019-08-15 Memorial Sloan-Kettering Cancer Center Non-hla restricted t cell receptors and uses thereof
WO2022093333A1 (en) * 2020-10-27 2022-05-05 T-Cure Biosciences, Inc. Recombinant t-cell receptors that bind the ny-eso-1 and/or lage-1a cancer antigens
US20240425563A1 (en) * 2021-01-13 2024-12-26 Washington University MHC-INDEPENDENT TCRs AND METHODS OF MAKING AND USING SAME
PE20240779A1 (es) * 2021-07-27 2024-04-17 Immatics Biotechnologies Gmbh Proteinas de union a antigenos que se unen especificamente a ct45
EP4527849A1 (en) 2023-09-19 2025-03-26 Universitätsmedizin der Johannes Gutenberg-Universität Mainz Hla-independent antigen binders, such as t-cell receptors, against pd-l1

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0486572B1 (en) * 1989-08-11 1998-01-07 Amrad Corporation Limited Improvements in granulocyte-macrophage colony-stimulating factor receptor and derivatives thereof
US5840839A (en) * 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
AU2002243444A1 (en) * 2000-10-31 2002-06-24 Diadexus, Inc. Compositions and methods relating to colon specific genes and proteins
MX2008012291A (es) * 2006-03-27 2009-01-12 Medimmune Ltd Miembro que enlaza al receptor gm-csf.
CA2651174A1 (en) * 2006-05-03 2007-11-15 Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services Chimeric t cell receptors and related materials and methods of use
US8088379B2 (en) 2006-09-26 2012-01-03 The United States Of America As Represented By The Department Of Health And Human Services Modified T cell receptors and related materials and methods
WO2008052277A1 (en) * 2006-11-03 2008-05-08 St. Vincent's Institute Of Medical Research Crystalline composition of gm-csf/gm-csfr
WO2010088160A1 (en) 2009-01-28 2010-08-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors and related materials and methods of use
WO2011029126A1 (en) * 2009-09-14 2011-03-17 Walter And Eliza Hall Institute Of Medical Research Methods and reagents for producing antibodies against autoantigens
HRP20171164T1 (hr) * 2010-09-20 2017-10-20 Biontech Cell & Gene Therapies Gmbh Antigen-specifični t stanični receptori i t stanični epitopi

Also Published As

Publication number Publication date
EP2932264A1 (en) 2015-10-21
TR201905447T4 (tr) 2019-05-21
CA3108192A1 (en) 2014-06-19
EP2932264B1 (en) 2019-01-30
US20180099033A1 (en) 2018-04-12
SI2932264T1 (sl) 2019-05-31
CA3108192C (en) 2026-02-24
US20150313978A1 (en) 2015-11-05
JP2016501268A (ja) 2016-01-18
AU2013357239B2 (en) 2019-10-17
PL2932264T3 (pl) 2019-09-30
PT2932264T (pt) 2019-05-21
CA2894966A1 (en) 2014-06-19
JP6475166B2 (ja) 2019-02-27
AU2019236675B2 (en) 2022-02-24
CA2894966C (en) 2021-03-30
DK2932264T3 (da) 2019-05-06
HUE042967T2 (hu) 2019-07-29
AU2013357239A1 (en) 2015-06-18
WO2014091034A1 (en) 2014-06-19
AU2019236675A1 (en) 2019-10-17
US10987413B2 (en) 2021-04-27
US9861688B2 (en) 2018-01-09

Similar Documents

Publication Publication Date Title
ES2721159T3 (es) Antígenos asociados a tumor independientes de MHC novedosos
ES2540858T3 (es) Composición farmacéutica para el tratamiento y/o la prevención de cáncer
AR122964A2 (es) Péptidos útiles en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cáncer
CO2019010524A2 (es) Plataforma de identificación de péptidos inmunogénicos basada en población
ES2545895T3 (es) Proteína de fusión anticancerígena
CR20170419A (es) Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer.
CL2019003426A1 (es) Nuevos péptidos (seq id n°174), combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer. (divisional solicitud 201800545)
MX2019006727A (es) Nuevos receptores de celulas t y terapia inmunologica que los utiliza.
MX2016015383A (es) Receptores de celulas t anti - papilomavirus 16 e7 humano.
CR20180027A (es) Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la misma terapia contra el cáncer epitelial de ovario y otros tipos de cáncer.
PE20190335A1 (es) Receptores de celulas t
CY1120430T1 (el) Ανασυνδυασμενες cdv συνθεσεις και χρησεις αυτων
CL2017001071A1 (es) Método para la cuantificación absoluta de péptidos cancerígenos hla-restringidos procesados naturalmente
BR112019008369A2 (pt) ácidos ribonucleicos mensageiros para intensificar respostas imunes e métodos para uso dos mesmos
UY36539A (es) Proteínas de unión a icos
CL2018000232A1 (es) Mezcla de péptidos (divisional solicitud 201601405)
BR112014008694A2 (pt) moléculas de ácido nucleico policistrônico recombinante
MX355074B (es) Inmunoterapia novedosa contra varios tumores incluidos el cancer gastrico y gastrointestinal.
EA201400912A1 (ru) Рекомбинантные поксвирусные векторы, экспрессирующие белки вируса бешенства и ox40, и вакцины, созданные на их основе
PE20141561A1 (es) Anticuerpos anti-lrp5 y metodos de uso
ES2722773T3 (es) Polipéptidos de fHbp meningocócicos modificados
BR112016016103A2 (pt) Composição de antígenos micobacterianos
EA201790296A1 (ru) Вакцина в виде рекомбинантного вектора на основе птичьего аденовируса серотипа 9
CY1125328T1 (el) Ανασυνδυασμενο εμβολιο ιου λευχαιμιας αιλουροειδων περιεχοντας βελτιστοποιημενο γονιδιο φακελου ιου λευχαιμιας αιλουροειδων
MX369413B (es) Peptido.